Compare DRD & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | TYRA |
|---|---|---|
| Founded | 1895 | 2018 |
| Country | South Africa | United States |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | DRD | TYRA |
|---|---|---|
| Price | $24.26 | $28.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $32.63 | ★ $47.50 |
| AVG Volume (30 Days) | 247.8K | ★ 807.7K |
| Earning Date | 08-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.23 | N/A |
| Revenue Next Year | $30.12 | N/A |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.08 | $8.98 |
| 52 Week High | $39.37 | $40.65 |
| Indicator | DRD | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 42.75 |
| Support Level | $23.26 | $27.40 |
| Resistance Level | $32.74 | $31.57 |
| Average True Range (ATR) | 0.95 | 1.98 |
| MACD | 0.16 | 0.26 |
| Stochastic Oscillator | 53.47 | 42.12 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.